Synthesis of new 2-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-ylimino)thiazolidin-4-one derivatives as anti-MRSA and anti-H. pylori agents.
4-Thiazolidinone
Antibacterial activity
Gram-positive
Helicobacter pylori
Nitrofuran
Thiadiazole
Journal
BMC chemistry
ISSN: 2661-801X
Titre abrégé: BMC Chem
Pays: Switzerland
ID NLM: 101741142
Informations de publication
Date de publication:
27 May 2022
27 May 2022
Historique:
received:
29
05
2020
accepted:
13
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
In this work, we have synthesized twenty five new 2-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-ylimino)thiazolidin-4-one derivatives bearing an aryl or heteroaryl methylene group on position 5 of thiazolidinone and evaluated their antimicrobial activity against Gram-positive and -negative bacteria as well as three metronidazole resistant Helicobacter pylori strains. Most of the compounds were very potent towards tested Gram-positive bacteria and showed an antibacterial efficacy substantially greater than ampicillin as the reference drug. However, no effectiveness was observed for the Gram-negative microorganisms. The compounds 9, 20 and 29 exhibited strong antimicrobial activity against Helicobacter pylori strains (inhibition zone > 30 mm) in 100 μg/disc and (inhibition zone > 20 mm) in 50 μg/disc. Taking these findings together, it seems that these potent antibacterial derivatives could be considered as promising agents for developing new anti-infectious drugs against microorganisms resistant to currently available antibiotics.
Identifiants
pubmed: 35624517
doi: 10.1186/s13065-022-00829-7
pii: 10.1186/s13065-022-00829-7
pmc: PMC9145458
doi:
Types de publication
Journal Article
Langues
eng
Pagination
38Informations de copyright
© 2022. The Author(s).
Références
Org Biomol Chem. 2015 Sep 28;13(36):9388-97
pubmed: 26238045
Mol Divers. 2022 Apr;26(2):769-780
pubmed: 33484399
Eur J Med Chem. 2016 Nov 29;124:1093-1104
pubmed: 27792980
Iran J Pharm Res. 2013 Summer;12(3):281-7
pubmed: 24250634
Bioorg Chem. 2020 Nov;104:104276
pubmed: 32992280
Bioorg Med Chem Lett. 2000 Apr 17;10(8):715-7
pubmed: 10782671
EXCLI J. 2017 Jan 13;16:52-62
pubmed: 28435427
Int J Appl Basic Med Res. 2013 Jan;3(1):3-10
pubmed: 23776832
Eur J Med Chem. 2014 Jan 24;72:52-77
pubmed: 24355348
Mini Rev Med Chem. 2019;19(3):239-249
pubmed: 30332951
Biochem Res Int. 2016;2016:8086762
pubmed: 26925267
Bioorg Chem. 2019 May;86:126-136
pubmed: 30690336
Chem Biol Interact. 2018 Apr 25;286:119-131
pubmed: 29574026
Drug Des Devel Ther. 2018 May 31;12:1545-1566
pubmed: 29910602
Bioorg Med Chem. 2012 Jun 1;20(11):3378-95
pubmed: 22546204
Front Pharmacol. 2017 Dec 04;8:889
pubmed: 29255418
J Enzyme Inhib Med Chem. 2017 Dec;32(1):746-758
pubmed: 28537532
Bioorg Med Chem. 2006 Jun 1;14(11):3859-64
pubmed: 16488614
Bioorg Chem. 2019 Mar;83:6-19
pubmed: 30339863
Bioorg Med Chem. 2018 Sep 1;26(16):4664-4676
pubmed: 30107969
Arch Pharm (Weinheim). 2006 Nov;339(11):621-4
pubmed: 17036368
Bioorg Med Chem Lett. 2017 Jul 1;27(13):3003-3006
pubmed: 28512023